Investigational drug · Phase 3
Deramiocel
Also called: CAP-1002, Allogeneic Cardiosphere-Derived Cells
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Deramiocel"
First trial start
2020
Aug 5, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Deramiocel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Disorders, Atrophic
- Muscular Diseases
- Neuromuscular Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn
- Nervous System Diseases
- Duchenne Muscular Dystrophy
Approved drugs for the same conditions: Duchenne muscular dystrophy · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Deramiocel" as an intervention, largest first.
- A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyPivotal-lookingActive, not recruiting
Capricor Inc.Industry
NCT05126758 · 106 participants · Start Jun 22, 2022 · Primary completion Jun 18, 2025
Drug: Deramiocel; Placebo · For: Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic and 5 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 20 sites in all
- A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyCompleted
Capricor Inc.Industry
NCT03406780 · 20 participants · Start Apr 4, 2018 · Primary completion Mar 10, 2020
Drug: CAP-1002; Placebo · For: Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic and 5 more
Sites: Sacramento, California; Aurora, Colorado; Orlando, Florida · 9 sites in all
- Open-label Extension of the HOPE-2 TrialActive, not recruiting
Capricor Inc.Industry
NCT04428476 · 13 participants · Start Aug 5, 2020 · Primary completion Feb 16, 2022
Drug: Deramiocel (CAP-1002) · For: Duchenne Muscular Dystrophy
Sites: Sacramento, California; Aurora, Colorado; St Louis, Missouri · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.
McDonald CM, Villa C, Soslow JH, et al. · Lancet 2026
- Reductions in myocardial interstitial fibrosis are dissociated from LV chamber stiffness in swine with repetitive pressure overload.
Hudson E, Gilligan A, Canty JM, et al. · Am J Physiol Heart Circ Physiol 2026
- A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel.
Li Y, Nice JB, Kozinova M, et al. · Biomedicines 2025
- Biological and genetic therapies for the treatment of Duchenne muscular dystrophy.
Wilton-Clark H, Yokota T · Expert Opin Biol Ther 2023
- Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy.
Kracht KD, Eichorn NL, Berlau DJ · Expert Opin Pharmacother 2022
- Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
McDonald CM, Marbán E, Hendrix S, et al. · Lancet 2022
Also in development for Muscular Dystrophies
- AOC 1044Phase 33 trials
Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44
- Zeleciment RostudirsenDYNE-251Phase 32 trials
Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)
- SAT-3247Phase 22 trials
Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.